Veliparib Plus Carboplatin/Paclitaxel in BRCA-Mutated, HER2-Negative Advanced Breast Cancer

<p><span data-sheets-value= "{"1":2,"2":"<p>We'll discuss the efficacy of a triplet combination therapy in <i>BRCA</i>-mutated, HER2-negative advanced breast cancer. Then, we'll move on to a report that detailed multiorgan immunotherapy-related adverse events in patients treated with atezolizumab. Last, we'll review the FDA's approval of the RET-targeted therapy pralsetinib in patients with metastatic RET fusion–positive non–small cell lung cancer.</p><p><b>Coverage of stories discussed this week on ascopost.com:</b></p><p><a href=\"https://ascopost.com/news/september-2020/addition-of-veliparib-to-carboplatinpaclitaxel-in-previously-treated-patients-with-brca-mutated-advanced-breast-cancer/\">Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With </a><i><a href=\"https://ascopost.com/news/september-2020/addition-of-veliparib-to-carboplatinpaclitaxel-in-previously-treated-patients-with-brca-mutated-advanced-breast-cancer/\">BRCA</a></i><a href=\"https://asco...